Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company’s product candidates include FPA008, an antibody that inhibits colony stimulating factor-1 receptor and is in Phase Ib clinical trials for the treatment of rheumatoid arthritis; and in pre-IND stage for pigmented villonodular synovitis and multiple cancers in combination with nivolumab. Its product candidates also comprise FPA144, an antibody that inhibits fibroblast growth factor receptor 2b and is in Phase I clinical trials to treat patients with gastric cancer; and FP-1039/GSK3052230, a fus...
Two Corporate Drive
South San Francisco, CA 94080
Founded in 2001
Five Prime Therapeutics, Inc. Presents at Credit Suisse 2015 Antibody Day, May-06-2015 03:00 PM
Apr 29 15
Five Prime Therapeutics, Inc. Presents at Credit Suisse 2015 Antibody Day, May-06-2015 03:00 PM. Venue: Credit Suisse, One Madison Avenue at 24th Street, 12th Floor, New York, New York, United States. Speakers: Aron Marc Knickerbocker, Chief Business Officer, Senior Vice President and Director, Brian Wong, Head of Immuno-Oncology and Vice President of Research.
Five Prime Therapeutics, Inc. - Analyst/Investor Day
Apr 22 15
To give in-depth presentations covering the biology, clinical development programs and target indications for two antibody therapeutics, FPA008 and FPA144, as well as provide a closer look into the company's immuno-oncology discovery platform and recent activities
Five Prime Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter and Year Ended December 31, 2014; Provides Cash Flow Guidance for the Full Year 2015
Mar 17 15
Five Prime Therapeutics, Inc. reported earnings results for the fourth quarter and year ended December 31, 2014. For the quarter, the company reported collaboration revenue of $4,645,000 against $3,785,000 a year ago. Loss from operations was $11,894,000 against $7,334,000 a year ago. Net loss was $11,826,000 or $0.55 per basic and diluted share against $7,317,000 or $0.43 per basic and diluted share a year ago. Collaboration revenue for the fourth quarter of 2014 increased by $0.8 million primarily due to revenue recognized under the immuno-oncology research collaboration with BMS.
For the full year, the company reported collaboration revenue of $19,231,000 against $13,791,000 a year ago. Loss from operations was $37,574,000 against $29,421,000 a year ago. Net loss was $37,424,000 or $1.79 per basic and diluted share against $28,872,000 or $5.23 per basic and diluted share a year ago. This increase in net loss was primarily related to advancing the FPA144 program into a phase 1 clinical trial and expanding internal immuno-oncology discovery efforts. Collaboration revenue for the full year 2014 increased by $5.4 million primarily due to revenue recognized under the collaborations with UCB, GSK, and BMS.
The company expects full year 2015 net cash used in operating activities to be less than $65 million and estimates ending 2015 with more than $160 million in cash, cash equivalents and marketable securities.